UroLume stents: Lessons learned

Tracey S. Wilson, Gary E. Lemack, Roger R. Dmochowski

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: The UroLume (American Medical Systems, Minnetonka, Minnesota) endoprosthesis has been commercially available since 1990 and has been advocated for use in men with urethral stricture disease and detrusor-sphincter dyssynergia due to spinal cord injury. Despite reports of its success and ease of removal, we have noted management problems in several complex cases. Materials and Methods: We retrospectively analyzed the outcome of 10 men who required several additional procedures or experienced complications following UroLume placement. Results: Of the patients 4 had detrusor-sphincter dyssynergia and 6 had urethral stricture disease. All patients with detrusor-sphincter dyssynergia required hospitalization for management of urosepsis within 4 to 10 months of stent placement, and all 4 experienced stent migration requiring placement of a tandem stent (3), bladder neck resection (3) or sphincterotomy (1). Two men were in retention following placement of a second stent and required stent explantation. Of the other 6 men 2 had bulbar and 3 had membranous urethral disease, and 1 had a severe bladder neck contracture following radical retropubic prostatectomy. Strictures recurred within the stent lumen in all 6 men and/or adjacent to it in 3. At least 1 repeat procedure was required in all 6 men (within 6 months in 5), and 1 experienced significant bleeding during open explantation which required perineal urethrostomy. Conclusions: In our referral experience stent migration and recurrent stenosis were noted following UroLume insertion. Placement of a tandem stent was associated with urethral obstruction. In many cases these adverse outcomes may be secondary to improper patient selection. Therefore, judicious use of the UroLume stent and proper case selection are essential since stent removal is not always straightforward.

Original languageEnglish (US)
Pages (from-to)2477-2480
Number of pages4
JournalJournal of Urology
Volume167
Issue number6
StatePublished - 2002

Fingerprint

Stents
Urethral Diseases
Ataxia
Urethral Stricture
Pathologic Constriction
Urinary Bladder
Urethral Obstruction
Contracture
Prostatectomy
Spinal Cord Injuries
Patient Selection
Hospitalization
Referral and Consultation
Hemorrhage

Keywords

  • Ataxia
  • Stents
  • Urethral stricture

ASJC Scopus subject areas

  • Urology

Cite this

Wilson, T. S., Lemack, G. E., & Dmochowski, R. R. (2002). UroLume stents: Lessons learned. Journal of Urology, 167(6), 2477-2480.

UroLume stents : Lessons learned. / Wilson, Tracey S.; Lemack, Gary E.; Dmochowski, Roger R.

In: Journal of Urology, Vol. 167, No. 6, 2002, p. 2477-2480.

Research output: Contribution to journalArticle

Wilson, TS, Lemack, GE & Dmochowski, RR 2002, 'UroLume stents: Lessons learned', Journal of Urology, vol. 167, no. 6, pp. 2477-2480.
Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: Lessons learned. Journal of Urology. 2002;167(6):2477-2480.
Wilson, Tracey S. ; Lemack, Gary E. ; Dmochowski, Roger R. / UroLume stents : Lessons learned. In: Journal of Urology. 2002 ; Vol. 167, No. 6. pp. 2477-2480.
@article{f29f70951bf24ae7a8aab2ccfed02466,
title = "UroLume stents: Lessons learned",
abstract = "Purpose: The UroLume (American Medical Systems, Minnetonka, Minnesota) endoprosthesis has been commercially available since 1990 and has been advocated for use in men with urethral stricture disease and detrusor-sphincter dyssynergia due to spinal cord injury. Despite reports of its success and ease of removal, we have noted management problems in several complex cases. Materials and Methods: We retrospectively analyzed the outcome of 10 men who required several additional procedures or experienced complications following UroLume placement. Results: Of the patients 4 had detrusor-sphincter dyssynergia and 6 had urethral stricture disease. All patients with detrusor-sphincter dyssynergia required hospitalization for management of urosepsis within 4 to 10 months of stent placement, and all 4 experienced stent migration requiring placement of a tandem stent (3), bladder neck resection (3) or sphincterotomy (1). Two men were in retention following placement of a second stent and required stent explantation. Of the other 6 men 2 had bulbar and 3 had membranous urethral disease, and 1 had a severe bladder neck contracture following radical retropubic prostatectomy. Strictures recurred within the stent lumen in all 6 men and/or adjacent to it in 3. At least 1 repeat procedure was required in all 6 men (within 6 months in 5), and 1 experienced significant bleeding during open explantation which required perineal urethrostomy. Conclusions: In our referral experience stent migration and recurrent stenosis were noted following UroLume insertion. Placement of a tandem stent was associated with urethral obstruction. In many cases these adverse outcomes may be secondary to improper patient selection. Therefore, judicious use of the UroLume stent and proper case selection are essential since stent removal is not always straightforward.",
keywords = "Ataxia, Stents, Urethral stricture",
author = "Wilson, {Tracey S.} and Lemack, {Gary E.} and Dmochowski, {Roger R.}",
year = "2002",
language = "English (US)",
volume = "167",
pages = "2477--2480",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - UroLume stents

T2 - Lessons learned

AU - Wilson, Tracey S.

AU - Lemack, Gary E.

AU - Dmochowski, Roger R.

PY - 2002

Y1 - 2002

N2 - Purpose: The UroLume (American Medical Systems, Minnetonka, Minnesota) endoprosthesis has been commercially available since 1990 and has been advocated for use in men with urethral stricture disease and detrusor-sphincter dyssynergia due to spinal cord injury. Despite reports of its success and ease of removal, we have noted management problems in several complex cases. Materials and Methods: We retrospectively analyzed the outcome of 10 men who required several additional procedures or experienced complications following UroLume placement. Results: Of the patients 4 had detrusor-sphincter dyssynergia and 6 had urethral stricture disease. All patients with detrusor-sphincter dyssynergia required hospitalization for management of urosepsis within 4 to 10 months of stent placement, and all 4 experienced stent migration requiring placement of a tandem stent (3), bladder neck resection (3) or sphincterotomy (1). Two men were in retention following placement of a second stent and required stent explantation. Of the other 6 men 2 had bulbar and 3 had membranous urethral disease, and 1 had a severe bladder neck contracture following radical retropubic prostatectomy. Strictures recurred within the stent lumen in all 6 men and/or adjacent to it in 3. At least 1 repeat procedure was required in all 6 men (within 6 months in 5), and 1 experienced significant bleeding during open explantation which required perineal urethrostomy. Conclusions: In our referral experience stent migration and recurrent stenosis were noted following UroLume insertion. Placement of a tandem stent was associated with urethral obstruction. In many cases these adverse outcomes may be secondary to improper patient selection. Therefore, judicious use of the UroLume stent and proper case selection are essential since stent removal is not always straightforward.

AB - Purpose: The UroLume (American Medical Systems, Minnetonka, Minnesota) endoprosthesis has been commercially available since 1990 and has been advocated for use in men with urethral stricture disease and detrusor-sphincter dyssynergia due to spinal cord injury. Despite reports of its success and ease of removal, we have noted management problems in several complex cases. Materials and Methods: We retrospectively analyzed the outcome of 10 men who required several additional procedures or experienced complications following UroLume placement. Results: Of the patients 4 had detrusor-sphincter dyssynergia and 6 had urethral stricture disease. All patients with detrusor-sphincter dyssynergia required hospitalization for management of urosepsis within 4 to 10 months of stent placement, and all 4 experienced stent migration requiring placement of a tandem stent (3), bladder neck resection (3) or sphincterotomy (1). Two men were in retention following placement of a second stent and required stent explantation. Of the other 6 men 2 had bulbar and 3 had membranous urethral disease, and 1 had a severe bladder neck contracture following radical retropubic prostatectomy. Strictures recurred within the stent lumen in all 6 men and/or adjacent to it in 3. At least 1 repeat procedure was required in all 6 men (within 6 months in 5), and 1 experienced significant bleeding during open explantation which required perineal urethrostomy. Conclusions: In our referral experience stent migration and recurrent stenosis were noted following UroLume insertion. Placement of a tandem stent was associated with urethral obstruction. In many cases these adverse outcomes may be secondary to improper patient selection. Therefore, judicious use of the UroLume stent and proper case selection are essential since stent removal is not always straightforward.

KW - Ataxia

KW - Stents

KW - Urethral stricture

UR - http://www.scopus.com/inward/record.url?scp=0036093215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036093215&partnerID=8YFLogxK

M3 - Article

C2 - 11992061

AN - SCOPUS:0036093215

VL - 167

SP - 2477

EP - 2480

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -